Ractigen Therapeutics, a clinical-stage biotechnology company developing small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, announced on Wednesday the successful closing of a new financing round exceeding USD31m (over CNY200m).

The round was led by Guozhong Capital, with participation from IDG Capital, China Everbright Limited, Jolmo Capital, Win-Win Capital, and SND Financial Holdings. Existing shareholder Longmen Capital, participated for its third consecutive round.

Proceeds from this financing round will primarily be used to accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies.